S'abonner

Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation - 05/02/20

Doi : 10.1016/j.ahj.2019.11.010 
Joanne S. Sutter, MD a, , Yuliya Lokhnygina, PhD a, James P. Daubert, MD a, b, Tristram Bahnson, MD a, b, Kevin Jackson, MD a, b, Jason I. Koontz, MD a, b, Albert Y. Sun, MD a, b, Donald D. Hegland, MD a, b, Kevin L. Thomas, MD a, b, Larry Jackson, MD a, b, Robert Lewis, MD, PhD a, b, Christopher Granger, MD a, Jonathan P. Piccini, MD, MHS a, b, Brett D. Atwater, MD a, b
a Duke University Medical Center, Durham, NC 
b Duke Center for Atrial Fibrillation, Durham, NC 

Reprint requests: Joanne Sutter, MD, Duke University Medical Center, Durham, NC 27705.Duke University Medical CenterDurhamNC27705

Abstract

Background

Pulmonary wall isolation (PWI) is increasingly used as an adjunctive lesion set to compliment pulmonary vein isolation (PVI), especially in patients with persistent atrial fibrillation (AF). The objective was to compare outcomes of catheter ablation in patients with persistent AF undergoing PVI with and without adjunctive PWI.

Methods

We performed a retrospective study of 558 patients who underwent de novo and repeat ablation for persistent AF. Subjects were matched using propensity score adjustments. Outcomes were freedom from recurrent atrial arrhythmia and adverse events.

Results

Among 558 patients who underwent ablation for persistent AF, 78 (14%) underwent PVI + PWI, 255 (46%) underwent PVI, and 225 (40%) underwent PVI + linear ablation. Stratified logistic regression analysis with propensity matching revealed higher odds of recurrent arrhythmia with PVI + PWI when compared to PVI (odds ratio [OR] 2.25, 95% CI 1.08-4.69, P = .030) and when compared to PVI + linear (OR 2.31, 95% CI 1.01-5.28, P = .048). Within the PVI + PWI group, 57.7% of subjects were in normal sinus rhythm at 6 months compared to 73.9% and 72.2% in PVI and PVI + linear groups, respectively. Adverse events were rare, with 19 events total identified across all groups.

Conclusions

PVI + PWI does not appear to be as effective as PVI or PVI + linear ablation in reducing the recurrence of arrhythmia within 6 months of the index procedure in patients with persistent AF. A prospective, randomized controlled trial comparing these ablation techniques is needed to clarify the role of extensive substrate modification for treatment of persistent AF.

Condensed Abstract

PWI is increasingly used as an adjunctive lesion set to compliment PVI in patients with persistent AF. We performed a retrospective study of 558 patients who underwent de novo and repeat ablation for persistent AF to compare the outcomes between PVI with and without adjunctive PWI. We found an increased incidence in recurrence of AF and other atrial arrhythmias at 6 months in the PVI + PWI cohort compared to PVI with or without additional linear ablation. A prospective, randomized controlled trial comparing these ablation techniques is needed to clarify the role of extensive substrate modification for treatment of persistent AF.

Le texte complet de cet article est disponible en PDF.

Plan


 Conflicts of interest: A. Y. S. reports grants for clinical research and education from Medtronic, Biosense Webster, and Merit Medical and serves on the advisory board for Merit Medical. J. P. P. reports grants for clinical research from Abbott, Boston Scientific, and JNJ and serves as a consultant to Abbott and Medtronic. The remaining authors have no conflicts of interest to disclose.
 Anna Gundlund, MD, PhD, served as guest editor for this article.


© 2019  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 220

P. 89-96 - février 2020 Retour au numéro
Article précédent Article précédent
  • Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
  • Gaetano M. De Ferrari, Susanna R. Stevens, Giuseppe Ambrosio, Sergio Leonardi, Paul W. Armstrong, Jennifer B. Green, Malgorzata Wamil, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study Group
| Article suivant Article suivant
  • Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
  • Marat Fudim, Jacob P. Kelly, Aaron D. Jones, Omar F. AbouEzzeddine, Andrew P. Ambrosy, Stephen J. Greene, Yogesh N.V. Reddy, Kevin J. Anstrom, Brooke Alhanti, Gregory D. Lewis, Adrian F. Hernandez, G. Michael Felker

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.